Cooperative Agreement UG1CA189861

The Georgia Colorectal Cancer Control Program (GCRCCP) is a $683,951 Cooperative Agreement awarded by the National Center for Chronic Disease Prevention and Health Promotion (CFDA 93.800 - Organized Approaches to Increase Colorectal Cancer Screening) to the Georgia Center for Oncology Research and Education, Inc. The purpose of the program is to increase colorectal cancer screening rates among the underserved rural populations in Georgia by providing evidence-based interventions through a...

This $1,351,734.00 Cooperative Agreement award was provided by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to the Medstar Health Research Institute Inc. to increase delivery of practical geriatric assessment in community oncology settings. The goal is to improve outcomes for older adult cancer patients (age 65+) through personalized treatment plans that account for domains of aging. The project will compare the use of ASCO educational materials alone...

The National Cancer Institute (NCI) awarded a $1,684,165 Cooperative Agreement under the 21st Century Cures Act - Beau Biden Cancer Moonshot (CFDA 93.353) to Kaiser Foundation Hospitals, doing business as Kaiser Permanente, to develop and evaluate strategies for increasing guideline-concordant lung cancer screening in Federally Qualified Health Centers (FQHCs). The project, titled "Expanding Lung Cancer Screening to Achieve Excellence (EXHALE)," will form a partnership between 7 FQHC...

This $1,006,599 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support the expansion of NCI-sponsored clinical research on hematologic malignancies to the Brooklyn and Queens catchment areas served by the Meyer Cancer Center (MCC) at Weill Cornell Medicine and NewYork-Presbyterian. The grant will fund the MCC's efforts to integrate interdisciplinary research and advance cancer prevention, treatment, and educational outreach in these underserved...

This Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), will fund a study to evaluate the impact of social determinants of health (SDOH) on early-onset colorectal cancer (EOCRC) diagnosis, treatment delays, and survival, with a focus on underserved populations in Kentucky and Georgia. The $192,610 award will support a 2-year epidemiologic study that aims to elucidate the relationship between SDOH measures and...

The National Cancer Institute (NCI) awarded a $2,336,229 Cooperative Agreement under the Cancer Centers Support Grants program (CFDA 93.397) to the University of Miami for the "Personalized Outreach and Multifaceted Interventions for Screening Enhancement (PROMISE) for Anal and Cervical Cancer Prevention and Treatment" project. This 5-year award, effective September 5, 2025, will leverage the expertise of three leading cancer research institutions - University of Miami's Sylvester...

This $248,194 Cooperative Agreement award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will fund a project by Wake Forest University Health Sciences to develop and test a workflow called CORRECT (Collaborative Oncology, between Radiologists and Radiation Oncologists for the Evaluation of Contoured Targets). The CORRECT workflow aims to facilitate communication between radiation oncologists and radiologists in cancer treatment planning and surveillance...

The National Cancer Institute (NCI), under the CFDA 93.393 Cancer Cause and Prevention Research program, awarded a $1,406,642 Cooperative Agreement to Kaiser Foundation Hospitals on September 8, 2025. This funding will support the adaptation and implementation of an evidence-based patient navigation intervention for adolescent and young adult (AYA) cancer survivors. The project aims to improve care coordination, surveillance, and access to primary care services for this underserved patient...

The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $941,798 Cooperative Agreement to the Beckman Research Institute of the City of Hope to investigate the molecular mechanisms of RNA modification-mediated codon-biased translation in acute myeloid leukemia (AML). The research aims to elucidate how the enzyme ALKBH1 regulates codon-biased translation of oncogenic targets, which may promote AML development and therapy resistance. The 5-year project seeks to provide...

This federal Project Grant award, valued at $575,051.00 and effective from September 1, 2025 through August 31, 2030, was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to support research initiatives at the University of Arizona Cancer Center (UACC). The key objectives of this grant are to grow the clinical research enterprise at UACC, specifically by expanding the breadth of the clinical trial portfolio to serve the diverse patient populations within UACC's...